Novotech Awarded by Frost & Sullivan for Global Biotech Clinical Trials Excellence in APAC

Hitesh
Clinical

Novotech won the 2022 Asia-Pacific Contract Research Organization Company of the Year Award as a result of recent Frost & Sullivan research on the Asia-Pacific market for contract research organizations. The corporation has a regional presence in eleven Asia-Pacific (APAC) countries, including China, India, Thailand, Malaysia, Australia, and South Korea. The more than 2,500 team members at Novotech support end-to-end clinical development for more than 600 biotechnology clients and work on all stages of clinical trials in APAC, Europe, and North America.

Novotech offers a 360-degree approach to drug development for its biotech customers, beginning with feasibility studies and continuing with project management, data administration, support for regulatory submissions, and medical monitoring. The full-service CRO partners with the global biotech industry with a focus on carrying out their clinical programs in APAC, offering experienced teams with decades of operational knowledge and cutting-edge technology to enable excellent clinical trial support.

The therapeutic area experience includes:

  • Oncology and Hematology
  • Cell & Gene Therapy
  • Neurology
  • Cardiology
  • Vaccines
  • Endocrinology
  • Immunology
  • Infectious diseases
  • Gastroenterology
  • Respiratory illnesses

“Novotech has incorporated new technologies such as virtual trials, real-world evidence capabilities, and AI-driven clinical data, enabling it to add value to its services and undertake more extensive global trials. The company addresses the global drug development market’s unmet needs with a strong leadership focus that incorporates client-centric strategies with best-practice implementation.”

Azza Fazar, a Frost & Sullivan best practices research analyst

To increase its capacity for virtual clinical trials, Novotech partners and invests with numerous APAC-based providers, including ObvioHealth and Saama Technologies. Additionally, it provided accelerated clinical programs throughout Asia Pacific to enhance the biotech industry’s clinical trial activity throughout COVID-19.

“Novotech fosters partnerships in APAC, Europe, and the United States to ensure that its clients always have access to the very best in clinical development programs. It has established long-standing customer relationships and remains a trusted partner with a reputation for offering the overall best in the market.” With its customer-centric approach and strong overall performance, Novotech earns Frost & Sullivan’s 2022 Asia-Pacific Company of the Year Award in the contract research organization industry,

Azza Fazar, a Frost & Sullivan best practices research analyst

Frost & Sullivan bestows the Company of the Year award to the company in each industry that exhibits excellence in terms of growth strategy and execution. With respect to consumer value and market penetration, the award honors a high level of innovation in both products and technologies.

Companies in many regional and international markets are honored with Frost & Sullivan Best Practices awards for exhibiting exceptional achievement and excellent performance in leadership, technological innovation, customer service, and strategic product creation. For the purpose of identifying industry best practices, industry analysts compare market participants, evaluate performance, and conduct in-depth interviews, analysis, and substantial secondary research.

Next Post

How can digital truth assist the healthcare industry?

The role of virtual reality applications in the healthcare industry The transformations in healthcare over the past decade are remarkable. As healthcare develops at a high rate, one more factor has been added between doctors and patients: technology. It makes the service more efficient and even saves lives. The medical […]
thehealthco.info